Relationship between treatment regimens for visceral leishmaniasis and development of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse: A cohort study from Bangladesh.
Adolescent
Adult
Aged
Aged, 80 and over
Antiprotozoal Agents
/ therapeutic use
Bangladesh
/ epidemiology
Drug Therapy
/ methods
Drug Therapy, Combination
/ methods
Female
Humans
Incidence
Injections, Intramuscular
Leishmaniasis, Cutaneous
/ epidemiology
Leishmaniasis, Visceral
/ complications
Male
Middle Aged
Prospective Studies
Recurrence
Retrospective Studies
Treatment Outcome
Young Adult
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
17
04
2019
accepted:
23
07
2019
revised:
27
08
2019
pubmed:
16
8
2019
medline:
8
1
2020
entrez:
16
8
2019
Statut:
epublish
Résumé
We investigated the relationship of treatment regimens for visceral leishmaniasis (VL) with post-kala-azar dermal leishmaniasis (PKDL) and visceral leishmaniasis relapse (VLR) development. Study subjects included cohorts of patients cured of VL since treatment with monotherapy by sodium stibogluconate (SSG), miltefosine (MF), paromomycin intramuscular injection (PMIM), liposomal amphotericin B [AmBisome (AMB)] in a single dose (SDAMB) and in multidose (MDAMB), and combination therapies by AMB+PMIM, AMB+MF, and PMIM+MF. Follow up period was 4 years after treatment. Cohorts were prospective except SSG (retrospective) and MF (partially retrospective). We compared incidence proportion and rate in 100-person-4year of PKDL and VLR by treatment regimens using univariate and multivariate analysis. 974 of 984 enrolled participants completed the study. Overall incidence proportion for PKDL and VLR was 12.3% (95% CI, 10.4%-14.5%) and 7.0% (95% CI, 5.6%-8.8%) respectively. The incidence rate (95% CI) of PKDL and VLR was 14.0 (8.6-22.7) and 7.6 (4.1-14.7) accordingly. SSG cohort had the lowest incidence rate of PKDL at 3.0 (1.3-7.3) and VLR at 1.8 (0.6-5.6), followed by MDAMB at 8.2 (4.3-15.7) for PKDL and at 2.7 (0.9-8.4) for VLR. Development of PKDL and VLR is related with treatment regimens for VL. SSG and MDAMB resulted in less incidence of PKDL and VLR compared to other treatment regimens. MDAMB should be considered for VL as a first step for prevention of PKDL and VLR since SSG is highly toxic and not recommended for VL.
Sections du résumé
BACKGROUND
We investigated the relationship of treatment regimens for visceral leishmaniasis (VL) with post-kala-azar dermal leishmaniasis (PKDL) and visceral leishmaniasis relapse (VLR) development.
METHODS
Study subjects included cohorts of patients cured of VL since treatment with monotherapy by sodium stibogluconate (SSG), miltefosine (MF), paromomycin intramuscular injection (PMIM), liposomal amphotericin B [AmBisome (AMB)] in a single dose (SDAMB) and in multidose (MDAMB), and combination therapies by AMB+PMIM, AMB+MF, and PMIM+MF. Follow up period was 4 years after treatment. Cohorts were prospective except SSG (retrospective) and MF (partially retrospective). We compared incidence proportion and rate in 100-person-4year of PKDL and VLR by treatment regimens using univariate and multivariate analysis.
FINDINGS
974 of 984 enrolled participants completed the study. Overall incidence proportion for PKDL and VLR was 12.3% (95% CI, 10.4%-14.5%) and 7.0% (95% CI, 5.6%-8.8%) respectively. The incidence rate (95% CI) of PKDL and VLR was 14.0 (8.6-22.7) and 7.6 (4.1-14.7) accordingly. SSG cohort had the lowest incidence rate of PKDL at 3.0 (1.3-7.3) and VLR at 1.8 (0.6-5.6), followed by MDAMB at 8.2 (4.3-15.7) for PKDL and at 2.7 (0.9-8.4) for VLR.
INTERPRETATION
Development of PKDL and VLR is related with treatment regimens for VL. SSG and MDAMB resulted in less incidence of PKDL and VLR compared to other treatment regimens. MDAMB should be considered for VL as a first step for prevention of PKDL and VLR since SSG is highly toxic and not recommended for VL.
Identifiants
pubmed: 31415565
doi: 10.1371/journal.pntd.0007653
pii: PNTD-D-19-00619
pmc: PMC6711542
doi:
Substances chimiques
Antiprotozoal Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0007653Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Postgrad Med. 2013 Jul-Sep;59(3):226-8
pubmed: 24029204
PLoS Negl Trop Dis. 2017 Nov 16;11(11):e0005877
pubmed: 29145397
Antimicrob Agents Chemother. 2018 Feb 23;62(3):
pubmed: 29263075
PLoS Negl Trop Dis. 2011 Dec;5(12):e1433
pubmed: 22206030
PLoS Negl Trop Dis. 2016 Oct 24;10(10):e0005060
pubmed: 27776123
Indian J Med Res. 2008 Jul;128(1):10-1
pubmed: 18820352
J Infect Dis. 2007 Aug 15;196(4):591-8
pubmed: 17624846
PLoS Negl Trop Dis. 2009;3(1):e355
pubmed: 19159009
Am J Trop Med Hyg. 2013 Aug;89(2):345-53
pubmed: 23817330
Indian J Med Res. 2006 Mar;123(3):275-88
pubmed: 16778310
PLoS Negl Trop Dis. 2017 May 30;11(5):e0005635
pubmed: 28558062
Am J Trop Med Hyg. 2011 Jul;85(1):66-9
pubmed: 21734127
Public Health Genomics. 2010;13(6):362-7
pubmed: 20051670
Clin Infect Dis. 2019 Jul 2;69(2):251-258
pubmed: 30357373
PLoS Negl Trop Dis. 2014 Aug 21;8(8):e3020
pubmed: 25144317
PLoS Negl Trop Dis. 2014 Jan 02;8(1):e2611
pubmed: 24392171
Infect Dis Poverty. 2018 Aug 13;7(1):80
pubmed: 30099967
Clin Infect Dis. 2017 Jul 1;65(1):150-153
pubmed: 28520851
J Clin Microbiol. 2012 Apr;50(4):1478-9
pubmed: 22278840
PLoS One. 2017 Sep 28;12(9):e0185606
pubmed: 28957391
N Engl J Med. 2010 Feb 11;362(6):504-12
pubmed: 20147716
Lancet Infect Dis. 2003 Feb;3(2):87-98
pubmed: 12560194
Indian J Dermatol. 2013 May;58(3):241
pubmed: 23723490
Lancet Infect Dis. 2016 Dec;16(12):e304-e309
pubmed: 27692643
PLoS Negl Trop Dis. 2015 Oct 23;9(10):e0004118
pubmed: 26496648
Lancet Glob Health. 2014 Jan;2(1):e51-7
pubmed: 25104636